AR072425A1 - Uso de nifurtimox para el tratamiento de giardiasis - Google Patents
Uso de nifurtimox para el tratamiento de giardiasisInfo
- Publication number
- AR072425A1 AR072425A1 ARP090102439A ARP090102439A AR072425A1 AR 072425 A1 AR072425 A1 AR 072425A1 AR P090102439 A ARP090102439 A AR P090102439A AR P090102439 A ARP090102439 A AR P090102439A AR 072425 A1 AR072425 A1 AR 072425A1
- Authority
- AR
- Argentina
- Prior art keywords
- nifurtimox
- giardiasis
- treatment
- anthelmintic
- compositions containing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/15—Depsipeptides; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Tropical Medicine & Parasitology (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dispersion Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Fodder In General (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Catching Or Destruction (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Abstract
Reivindicacion 3: Composiciones que contienen nifurtimox y un antihelmíntico. Reivindicacion 4: Composiciones que contienen nifurtimox y un ciclooctadepsipéptido antihelmíntico.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102008031284A DE102008031284A1 (de) | 2008-07-02 | 2008-07-02 | Neue Bekämpfungsmöglichkeit der Giardiose |
Publications (1)
Publication Number | Publication Date |
---|---|
AR072425A1 true AR072425A1 (es) | 2010-08-25 |
Family
ID=41077987
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP090102439A AR072425A1 (es) | 2008-07-02 | 2009-06-30 | Uso de nifurtimox para el tratamiento de giardiasis |
Country Status (30)
Country | Link |
---|---|
US (1) | US8440612B2 (es) |
EP (1) | EP2310018B1 (es) |
JP (1) | JP5627579B2 (es) |
KR (1) | KR101720805B1 (es) |
CN (1) | CN102083441B (es) |
AR (1) | AR072425A1 (es) |
AU (1) | AU2009266125B2 (es) |
BR (1) | BRPI0913889B1 (es) |
CA (1) | CA2729730C (es) |
CL (2) | CL2010001577A1 (es) |
CO (1) | CO6321270A2 (es) |
CR (1) | CR20110022A (es) |
DE (1) | DE102008031284A1 (es) |
DK (1) | DK2310018T3 (es) |
DO (1) | DOP2010000405A (es) |
EC (1) | ECSP10010720A (es) |
ES (1) | ES2444581T3 (es) |
HK (1) | HK1158113A1 (es) |
IL (1) | IL209698A (es) |
MX (1) | MX2010014446A (es) |
MY (1) | MY157007A (es) |
NI (1) | NI201100008A (es) |
NZ (1) | NZ590276A (es) |
PE (1) | PE20110283A1 (es) |
PL (1) | PL2310018T3 (es) |
RU (1) | RU2538713C9 (es) |
SV (1) | SV2011003785A (es) |
UA (1) | UA103328C2 (es) |
WO (1) | WO2010000399A1 (es) |
ZA (1) | ZA201009225B (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2627322B1 (en) * | 2010-10-12 | 2017-08-02 | The U.S.A. as represented by the Secretary, Department of Health and Human Services | Methods of treating giardiasis |
PT3298027T (pt) | 2015-05-20 | 2022-01-26 | Boehringer Ingelheim Animal Health Usa Inc | Compostos depsipéptidos antelmínticos |
JP6943859B2 (ja) | 2015-12-28 | 2021-10-06 | ベーリンガー インゲルハイム アニマル ヘルス ユーエスエイ インコーポレイテッド | 駆虫性デプシペプチド化合物 |
MX2019005628A (es) | 2016-11-16 | 2019-12-18 | Boehringer Ingelheim Animal Health Usa Inc | Compuestos depsipeptidos antihelminticos. |
EP3750527A1 (en) * | 2019-06-13 | 2020-12-16 | Bayer AG | Stable tablet formulation of nifurtimox and process for producing the same |
CN114377018B (zh) * | 2020-10-21 | 2024-02-06 | 中国医学科学院药物研究所 | 硝呋莫司在制备抗流感病毒药物中的应用 |
Family Cites Families (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE1170957B (de) * | 1962-11-23 | 1964-05-27 | Bayer Ag | Verfahren zur Herstellung von 5-Nitro-furfuryliden-(2)-iminoderivaten |
JPH081908B2 (ja) * | 1987-07-22 | 1996-01-10 | 三菱電機株式会社 | 超格子半導体素子 |
NO176766C (no) * | 1989-02-07 | 1995-05-24 | Meiji Seika Kaisha | Fremgangsmåte for fremstilling av en forbindelse med anthelmintaktivitet |
CA2132199C (en) | 1992-03-17 | 2000-01-18 | Hitoshi Nishiyama | Depsipeptide derivative, production thereof and use thereof |
DE4317458A1 (de) | 1992-06-11 | 1993-12-16 | Bayer Ag | Verwendung von cyclischen Depsipeptiden mit 18 Ringatomen zur Bekämpfung von Endoparasiten, neue cyclische Depsipeptide mit 18 Ringatomen und Verfahren zu ihrer Herstellung |
CA2155871A1 (en) * | 1993-02-19 | 1994-09-01 | Makoto Ohyama | Derivatives of cyclodepsipeptide pf 1022 |
DE4317432A1 (de) | 1993-05-26 | 1994-12-01 | Bayer Ag | Octacyclodepsipeptide mit endoparasitizider Wirkung |
DE4317457A1 (de) * | 1993-05-26 | 1994-12-01 | Bayer Ag | Octacyclodepsipeptide mit endoparasitizider Wirkung |
JP3263947B2 (ja) | 1993-09-06 | 2002-03-11 | 藤沢薬品工業株式会社 | 環状デプシペプチド化合物 |
DE4401389A1 (de) * | 1994-01-19 | 1995-07-20 | Bayer Ag | Verwendung von cyclischen Depsipeptiden mit 12 Ringatomen zur Bekämpfung von Endoparasiten, neue cyclische Depsipeptide mit 12 Ringatomen und Verfahren zu ihrer Herstellung |
DE4406025A1 (de) * | 1994-02-24 | 1995-08-31 | Bayer Ag | Milchsäure-haltige cyclische Depsipeptide mit 18 Ringatomen als endoparasitizide Mittel und Verfahren zu ihrer Herstellung |
RU2074038C1 (ru) * | 1994-06-16 | 1997-02-27 | Товарищество с ограниченной ответственностью Предприятие "ТЕПАРК" | Способ изготовления полых металлических емкостей |
DE4437198A1 (de) | 1994-10-18 | 1996-04-25 | Bayer Ag | Verfahren zur Sulfonylierung, Sulfenylierung und Phosphorylierung von cyclischen Depsipeptiden |
ES2322678T3 (es) * | 1995-06-30 | 2009-06-24 | Astellas Pharma Inc. | Derivado de depsipeptido, procedimiento para su produccion y nuevo intermedio del mismo. |
DE69634961T2 (de) * | 1995-09-22 | 2006-04-20 | Bayer Ag | Neue zyklische depsipeptid pf1022 derivate |
DE19545639A1 (de) * | 1995-12-07 | 1997-06-12 | Bayer Ag | Verfahren zur Herstellung von substituierten Arylmilchsäure-haltigen Cyclodepsipeptiden mit 24 Ringatomen |
US6503881B2 (en) * | 1996-08-21 | 2003-01-07 | Micrologix Biotech Inc. | Compositions and methods for treating infections using cationic peptides alone or in combination with antibiotics |
US5874630A (en) * | 1998-01-06 | 1999-02-23 | Occidental Chemical Corporation | Synthesis of mercaptans from alcohols |
US6133228A (en) * | 1998-05-28 | 2000-10-17 | Firmenich Sa | Slow release of fragrant compounds in perfumery using 2-benzoyl benzoates, 2-alkanoyl benzoates or α-keto esters |
DE19828047A1 (de) * | 1998-06-24 | 1999-12-30 | Bayer Ag | Substituierte Cyclooctadepsipeptide |
CN101098694A (zh) * | 2004-11-12 | 2008-01-02 | 细胞基因公司 | 使用免疫调节化合物治疗和控制寄生性疾病的方法和组合物 |
DE102005033496A1 (de) * | 2005-07-19 | 2007-01-25 | Bayer Healthcare Ag | Desinfektionsmittel |
-
2008
- 2008-07-02 DE DE102008031284A patent/DE102008031284A1/de not_active Withdrawn
-
2009
- 2009-06-20 NZ NZ590276A patent/NZ590276A/xx not_active IP Right Cessation
- 2009-06-20 RU RU2011103475/15A patent/RU2538713C9/ru not_active IP Right Cessation
- 2009-06-20 CA CA2729730A patent/CA2729730C/en not_active Expired - Fee Related
- 2009-06-20 PL PL09772099T patent/PL2310018T3/pl unknown
- 2009-06-20 UA UAA201101135A patent/UA103328C2/uk unknown
- 2009-06-20 MX MX2010014446A patent/MX2010014446A/es active IP Right Grant
- 2009-06-20 JP JP2011515179A patent/JP5627579B2/ja not_active Expired - Fee Related
- 2009-06-20 MY MYPI2010006319A patent/MY157007A/en unknown
- 2009-06-20 DK DK09772099.9T patent/DK2310018T3/da active
- 2009-06-20 BR BRPI0913889A patent/BRPI0913889B1/pt not_active IP Right Cessation
- 2009-06-20 AU AU2009266125A patent/AU2009266125B2/en not_active Ceased
- 2009-06-20 WO PCT/EP2009/004475 patent/WO2010000399A1/de active Application Filing
- 2009-06-20 EP EP09772099.9A patent/EP2310018B1/de not_active Not-in-force
- 2009-06-20 CN CN2009801255081A patent/CN102083441B/zh not_active Expired - Fee Related
- 2009-06-20 US US13/000,715 patent/US8440612B2/en not_active Expired - Fee Related
- 2009-06-20 PE PE2010001201A patent/PE20110283A1/es not_active Application Discontinuation
- 2009-06-20 ES ES09772099.9T patent/ES2444581T3/es active Active
- 2009-06-20 KR KR1020117002111A patent/KR101720805B1/ko active IP Right Grant
- 2009-06-30 AR ARP090102439A patent/AR072425A1/es not_active Application Discontinuation
-
2010
- 2010-12-01 IL IL209698A patent/IL209698A/en active IP Right Grant
- 2010-12-22 ZA ZA2010/09225A patent/ZA201009225B/en unknown
- 2010-12-27 CO CO10162857A patent/CO6321270A2/es active IP Right Grant
- 2010-12-27 CL CL2010001577A patent/CL2010001577A1/es unknown
- 2010-12-27 EC EC2010010720A patent/ECSP10010720A/es unknown
- 2010-12-27 DO DO2010000405A patent/DOP2010000405A/es unknown
-
2011
- 2011-01-03 SV SV2011003785A patent/SV2011003785A/es active IP Right Grant
- 2011-01-05 NI NI201100008A patent/NI201100008A/es unknown
- 2011-01-11 CR CR20110022A patent/CR20110022A/es unknown
- 2011-11-25 HK HK11112838.8A patent/HK1158113A1/xx not_active IP Right Cessation
-
2013
- 2013-03-15 CL CL2013000709A patent/CL2013000709A1/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CL2008001633A1 (es) | Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer. | |
CO6321189A2 (es) | Compuestos de tiazol y oxazol de bencen-sulfonamida | |
NI201000055A (es) | 2' - fluoro - 2' - desoxitetrahidrouridinas como inhibidores de citidina desaminasa. | |
CL2012003293A1 (es) | Compuestos derivados de aminopirimidina, como moduladores de la proteina quinasa rica en repeticiones leucina 2 (lrrk2); composicion farmaceutica que los contiene; y su uso para el tratamiento terapeutico y/o profilactico de la enfermedad de parkinson. | |
CL2008001721A1 (es) | Compuestos derivados de 17-beta-ciano-18 alfa-homo-19-nor-androst-4-eno; que presentan actividad gestagena y antimineralcorticoide; composicion farmaceutica; y uso en el tratamiento de trastornos pre-peri-y posmenopausicos y trastornos premenstruales. | |
CL2011000691A1 (es) | Compuestos derivados de nicotinamida sustituida; composicion farmaceutica que los comprende; uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias. | |
CL2011000527A1 (es) | Compuestos derivados de benzofurano; composicion farmaceutica que los comprende;y su uso en el tratamiento de la hepatitis c. | |
CL2012002189A1 (es) | Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos. | |
CL2009000426A1 (es) | Compuestos derivados de carbociclil/heterociclil-piridin-2-il-urea, inhibidores de topoisomerasa iv bacteriana; composicion farmaceutica; y su uso para el tratamiento de infecciones bacterianas | |
CR11861A (es) | Compuestos organicos | |
CL2012003281A1 (es) | Uso de compuestos específicos estimuladores y/o activadores de sgc; formulacion farmaceutica que comprende dichos compuestos; kit que comprende los compuestos, y uso para la prevencion y/o tratamiento de la esclerosis sistematica. | |
CL2009000483A1 (es) | Compuestos derivados de n-(piridin-3-il)-1,3-tiazol-5-amino-4-carboxamida, inhibidores de cinasa pim; composicion farmaceutica; y uso para el tratamiento del cancer. | |
CL2008003284A1 (es) | Compuestos derivados de 4-bencilamino-1-carboxiacil-piridina, inhibidores cetp; composicion farmaceutica que los comprende; combinacion farmaceutica; y uso en el tratamiento de enfermedades metabolicas, ateroesclerosis y cardiovasculares, entre otras. | |
CL2007002492A1 (es) | Compuestos derivados de bi-,tri o policiclos no aromaticos, inhibidores de la enzima 11-beta-hidroxiesteroide deshidrogenasa tipo i; proceso de preparacion de estos; composicion famaceutica que los comprende; uso en el tratamiento de enfermedades tales como la obesidad, diabetes y dislipidemia, entre otras. | |
CL2011000846A1 (es) | Compuestos heterociclicos sustituidos; composicion farmaceutica; y su uso para el tratamiento de la hepatitis c. | |
CL2008002430A1 (es) | Compuestos derivados de bencenosulfonamida, inhibidores de catepsina c; composicion farmaceutica que los comprende; y su uso para el tratamiento de la epoc. | |
CL2008002295A1 (es) | Compuestos derivados de tiazolida sustituidos con alquilsulfonilos; composicion farmaceutica; y uso para el tratamiento de la hepatitis c. | |
CL2011002548A1 (es) | Compuestos derivados de resolviina; composicion farmaceutica; uso de la composicion; kit farmaceutico; combinacion farmaceutica; uso de los compuestos en el tratamiento y/o prevencion de una condicion oftalmica. | |
CL2011001331A1 (es) | Clorhidrato de nalmefeno dihidratado; métodos para su preparación; composición farmacéutica que lo comprende; y uso para el tratamiento del alcoholismo. | |
CL2009000309A1 (es) | Derivados fluoroglicosidos aromaticos, composicion farmaceutica que contenga estos compuestos, procedimiento para prepararla y su uso en el tratamiento de la diabetes tipo 1 y 2. | |
ECSP11011344A (es) | Nuevos anticuerpos anti-?5?1 y sus usos | |
GT201000047A (es) | Mejoras en compuestos organicos o relacionadas con los mismos | |
NI201400042A (es) | 2 - tiopirimidinonas | |
AR072425A1 (es) | Uso de nifurtimox para el tratamiento de giardiasis | |
UY29417A1 (es) | Agentes endoparasiticidas |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC | Refusal |